<DOC>
	<DOCNO>NCT02918071</DOCNO>
	<brief_summary>The purpose study assess functionality , performance , reliability single-use auto-injector ( AI ) benralizumab administer subcutaneously ( SC ) at-home set report patient caregiver , confirm safety clinical benefit benralizumab administration asthma patient severe asthma</brief_summary>
	<brief_title>Study Assess Functionality , Reliability , Performance Single-Use Auto-Injector With Benralizumab Administered Home</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion Written inform consent study participation must obtain prior study related procedure perform accord international guideline and/or applicable European Union ( EU ) guideline Male female patient age 18 75 year age time Visit 1 Patient caregiver must willing able selfadminister Investigational product ( IP ) . Caregiver must age consent old time Visit 1 , applicable Weight ≥40 kg Evidence asthma document airway reversibility ( FEV1 ≥12 % 200 ml ) demonstrate Visit 1 1A Visit 2 Documented history current treatment Inhaled corticosteroid ( ICS ) Longacting β2 agonist ( LABA ) . The ICS LABA part combination product give separate inhaler . The ICS dose must great equal 500 μg/day fluticasone propionate dry powder formulation equivalent daily . For ICS/LABA combination preparation , mid highstrength maintenance dose approved local country meet ICS criterion . Additional asthma controller medication ( e.g. , Leukotriene receptor antagonist ( LTRAs ) , tiotropium , theophylline , oral corticosteroid ) allow Prebronchodilator ( preBD ) FEV1 &gt; 50 % predict normal Visit 1 1A Visit 2 Not well control asthma document either : An Asthma Control Questionnaire 6 ( ACQ6 ) ≥1.5 OR ; A peak flow 6080 % predict OR ; One exacerbation require oral systemic corticosteroid previous year Exclusion criterion : Clinically important pulmonary disease asthma ( eg , active lung infection , COPD ( Chronic obstructive pulmonary disease ) , bronchiectasis , pulmonary fibrosis , cystic fibrosis , hypoventilation syndrome associate obesity , lung cancer , alpha 1 antitrypsin deficiency , primary ciliary dyskinesia ) ever diagnose pulmonary systemic disease , asthma , associate elevated peripheral eosinophil count ( eg , allergic bronchopulmonary aspergillosis/mycosis , ChurgStrauss syndrome , hypereosinophilic syndrome ) Any disorder , include , limited , cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , hematological , psychiatric , major physical impairment stable opinion Investigator could : Affect safety patient throughout study ; Influence finding study interpretation ; Impede patient 's ability complete entire duration study Known history allergy reaction IP formulation History anaphylaxis biologic therapy History GuillainBarré syndrome A helminth parasitic infection diagnose within 24 week prior date informed consent obtain treat , fail respond standard care therapy Acute upper low respiratory infection require antibiotic antiviral medication within 30 day prior date informed consent obtain screen Any clinically significant abnormal finding physical examination , vital sign , hematology , clinical chemistry , urinalysis screening period , opinion Investigator , may put patient risk his/her participation study , may influence result study , patient 's ability complete entire duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Asthma ,</keyword>
	<keyword>Bronchial Diseases ,</keyword>
	<keyword>Respiratory Tract Diseases ,</keyword>
	<keyword>Lung Diseases ,</keyword>
	<keyword>Obstructive Lung Diseases ,</keyword>
	<keyword>Benralizumab</keyword>
</DOC>